India, Nov. 19 -- Johnson & Johnson (JNJ), has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA seeking approval of CAPLYTA (lumateperone) for manic or mixed episodes associated with bipolar I disorder in adults.

The application is supported by two positive Phase 3 studies, in which once-daily CAPLYTA 42 mg significantly reduced manic symptoms compared with placebo, with improvements observed as early as Day 3 and sustained through Week 3.

The treatment was generally well tolerated, with low discontinuation rates and a safety profile consistent with earlier studies.

googletag.cmd.push(function() { googletag.display('div-gpt-ad-1568189509843-0'); });

If approved, bipolar mania would become CAPLYTA's fifth approved use...